US Patent 10918715 Treatment of severe community acquired pneumonia
Patent 10918715 was granted and assigned to Biotest AG on February, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+299 characters)
Article
Patent abstract
The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
109187150
Date of Patent
February 16, 2021
0Patent Application Number
167866390
Date Filed
February 10, 2020
0Official Website
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
109187150
Date of Patent
February 16, 2021
0Patent Application Number
167866390
Date Filed
February 10, 2020
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 10 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10918715 Treatment of severe community acquired pneumonia
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10918715
Date of patent
February 16, 2021
Patent application number
16786639
Date Filed
February 10, 2020
Patent primary examiner
Find more entities like US Patent 10918715 Treatment of severe community acquired pneumonia
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.